CACrown ArchivesThe cinema collection
Menu
Research dossier · General Reference

Complete Response Letter

regulatory action by the US Food and Drug Administration

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionFeb 23, 2026
Entity authorityQ107525125
Source-derived summary

In United States pharmaceutical regulatory practice, a Complete Response Letter (CRL), or more rarely, a 314.110 letter, is a regulatory action by the Food and Drug Administration in response to a New Drug Application, Amended New Drug Application or Biologics License Application, indicating that the application will not be approved in its present form. CRLs replaced approvable letters in 2018.

Background

Under the Prescription Drug User Fee Act, the Food and Drug Administration has a limited timespan (known as the PDUFA date) to decide a New Drug Application, Abbreviated New Drug Application or Biologics License Application. The FDA may either approve the application or issue a Complete Response Letter. Grounds behind issuing a CRL may include labeling issues, current Good Manufacturing Practice concerns or concerns about the safety or effectiveness of the drug.

A sponsor receiving CRL may withdraw the application, request a hearing or resubmit the application. Because hearings are open to the public, this course of action is relatively rarely chosen.

Class 1 and Class 2 resubmissions after CRLs

MAPP 6020 Rev. 2, the Food and Drug Administration policy manual governing resubmissions following a CRL, classifies CRLs as requiring a Class 1 or Class 2 resubmission. Where a sponsor decides to submit a response to a CRL, the response is classified within 30 days, if the response is complete.

Editorial summary

Begin with the source’s own compact description: “Complete Response Letter” is regulatory action by the US Food and Drug Administration. The dossier treats that line as a proposition to test through Complete, Response and Letter, not as a finished interpretation.

Editorial reviewA practical starting point whose main value is the path it opens into stronger specialist and primary sources. The current lead gives the account dated anchors—2018—that can be checked directly. The selected authority fields contribute no independent date. For this dossier, Complete, Response and Letter is the immediate research focus.
Editorial analysis

Why this record matters

The phrase “regulatory action by the US Food and Drug Administration” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.

Evidence profile

Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Feb 23, 2026. The linked authority identifier is Q107525125. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2018.

Critical limits

Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Complete Response Letter”, its source revision and the description used here.
  2. Expand the search: follow Complete Response Letter primary sources, Complete Response Letter archive and Complete research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Complete Response Letter”?
  2. What terminology or title could unlock a more precise catalogue search?
  3. Which cited source is closest to the event, object or claim?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from Complete Response Letter” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.